ALDA Pharmaceuticals Corp. Named as Part of 2010 TSX Venture 50
2/5/2010 10:15:38 AM - Market Wire
NEW WESTMINSTER, BRITISH COLUMBIA, Feb 05, 2010 (MARKETWIRE via COMTEX News Network) --
TSX Venture Exchange today announced that ALDA Pharmaceuticals Corp. (TSX VENTURE: APH) (the "Company" or "ALDA") has been named as one of the TSX Venture 50, a ranking of strong performers listed on TSX Venture Exchange. TSX Venture 50 is comprised of 10 emerging companies in five industry sectors that have been identified as leaders in Canada's public venture market.
"It is an honour to be named as part of this year's TSX Venture 50," said Dr. Terrance Owen, President & CEO. "Our listing on the TSX Venture Exchange has provided us with the ideal environment to meet our growth goals and objectives."
The 2010 TSX Venture 50 were selected based on four equally weighted criteria that include return on investment, trading, analyst coverage and market capitalization growth in Cleantech, Diversified Industries, Mining, Oil & Gas and Technology and Life Sciences sectors.
"We are pleased to celebrate the 2010 TSX Venture 50," said John McCoach, President, TSX Venture Exchange. "These outstanding companies are proven leaders in their respective sectors and we are proud to have them listed on TSX Venture Exchange. We wish them all continued success."
About ALDA Pharmaceuticals Corp.
ALDA is focused on the development of infection-control therapeutics derived from its patented T36(R) technology. The company trades on the TSX Venture Exchange under the symbol APH.
Terrance G. Owen, Ph.D., MBA, President & CEO
ALDA Pharmaceuticals Corp.